Nicotine Rewires Habenular Circuits in Mice, Altering Food Motivation

Tobacco use disorder remains a leading cause of preventable mortality, yet achieving long-term abstinence is notoriously difficult even with established pharmacotherapies. A meta-analysis of 10,110 patients demonstrates that varenicline yields a significantly higher continuous abstinence rate at 12 weeks compared to bupropion (odds ratio 1.79, 95% confidence interval 1.59 to 2.02, p < 0.001) [1]. This clinical challenge is compounded because nicotine dependence co-occurs in 33.4% to 65% of patients with severe mental illness [2] and physically alters brain architecture. Magnetic resonance imaging (MRI) data from nearly 3,000 individuals reveals decreased gray matter volume in the right anterior cingulate and altered intrinsic function within the default mode and salience networks (interconnected brain regions that govern self-reflection and the ability to focus on relevant stimuli) [3]. While researchers are currently conducting nine clinical trials to test whether glucagon-like peptide 1 receptor agonists, such as semaglutide, can curb nicotine cravings [4], clinicians must also navigate concurrent substance use. Data from 229,630 patients shows that cannabis co-use lowers the odds of successful tobacco cessation by 35% (odds ratio 0.65, p < 0.0001) [5]. A recent study now offers fresh insights into how chronic nicotine exposure physically rewires deep brain circuitry to alter baseline motivation for natural rewards, providing specific neurobiological targets to help improve future cessation therapies.